Biosimilar drugs are very similar to existing biologic drugs, but are not exact copies. They are designed to have similar safety, efficacy, and quality as the original biologic drug. Biosimilars are typically produced by different manufacturers once the original biologic drug's patent expires. This research area focuses on developing and testing biosimilars to ensure they are safe and effective for patients, as well as understanding the regulatory framework and market dynamics surrounding these products. Biosimilar drugs have the potential to increase access to essential treatments and lower healthcare costs.